Aileron Therapeutics (ALRN) Stock Price Up 2.8%

Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) rose 2.8% during mid-day trading on Wednesday . The company traded as high as $2.22 and last traded at $2.18. Approximately 13,220 shares traded hands during trading, a decline of 96% from the average daily volume of 306,823 shares. The stock had previously closed at $2.12.

ALRN has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. ValuEngine downgraded shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Finally, HC Wainwright initiated coverage on shares of Aileron Therapeutics in a report on Monday. They set a “buy” rating and a $7.00 price target on the stock.

The firm has a market capitalization of $27.73 million, a PE ratio of -1.08 and a beta of 3.18. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.19.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management Inc. boosted its holdings in Aileron Therapeutics by 78.6% during the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock worth $312,000 after buying an additional 50,000 shares in the last quarter. Vanguard Group Inc boosted its holdings in Aileron Therapeutics by 8.0% during the third quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock worth $265,000 after buying an additional 7,109 shares in the last quarter. Parkwood LLC purchased a new stake in Aileron Therapeutics during the third quarter worth $149,000. Finally, Renaissance Technologies LLC acquired a new position in Aileron Therapeutics during the third quarter worth $137,000. 9.16% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2019/03/15/aileron-therapeutics-alrn-stock-price-up-2-8.html.

Aileron Therapeutics Company Profile (NASDAQ:ALRN)

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Recommended Story: Momentum Investing

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.